[Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas]
/in Dendritic Cells, Glioblastoma, International PublicationsHost mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease VirusThe ‚kiss of death‘ by dendritic cells to cancer cells
/in Dendritic Cells, International PublicationsTherapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
/in HIV/AIDS, International PublicationsBreast cancer vaccines: promise for the future or pipe dream?
/in Breast Cancer, International PublicationsVaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein
/in Chronic Virus Hepatitis, International PublicationsNumerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
/in Breast Cancer, Dendritic Cells, International PublicationsDocetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
/in International Publications, NSCLCRecombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer